BI 3820768

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 3820768, covering 2026-03-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) [Phase 1]

See pricing